Abstract
The theoretical role of sigma receptors in psychosis has led to the development of selective sigma receptor ligands as potential antipsychotic agents. BMY 14802 has its most potent binding at the sigma binding site, with some degree of serotonin subtype 1A and negligible dopamine receptor binding. It is atypical of standard neuroleptics in that it does not induce catalepsy in rats. It has been shown to have efficacy in animal models of psychosis. It was hypothesized that the drug would have antipsychotic effects in humans without producing the extrapyramidal side effects typical of standard neuroleptics. We report here the results of an uncontrolled, multicenter safety and efficacy study of patients with acute exacerbations of schizophrenia treated with BMY 14802. After 1 week of single-blind placebo treatment, 28 patients were treated with BMY 14802 (up to 3000 mg/day) for up to 4 weeks. There was no significant improvement in psychiatric symptoms, as measured by the total Brief Psychiatric Rating Scale scores or Clinical Global Improvement. There were no changes in involuntary movements, as measured by the Abnormal Involuntary Movement Scale, or in extrapyramidal symptoms as measured by the Simpson-Angus Scale.
Similar content being viewed by others
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Gewirtz, G., Gorman, J., Volavka, J. et al. BMY 14802, a Sigma Receptor Ligand for the Treatment of Schizophrenia. Neuropsychopharmacol 10, 37–40 (1994). https://doi.org/10.1038/npp.1994.5
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/npp.1994.5
Keywords
This article is cited by
-
The effects of BMY-14802 against l-DOPA- and dopamine agonist-induced dyskinesia in the hemiparkinsonian rat
Psychopharmacology (2013)
-
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism
Psychopharmacology (2009)
-
Intrathecal treatment with σ1 receptor antagonists reduces formalin‐induced phosphorylation of NMDA receptor subunit 1 and the second phase of formalin test in mice
British Journal of Pharmacology (2006)
-
The highly efficacious actions of N-desmethylclozapine at muscarinic receptors are unique and not a common property of either typical or atypical antipsychotic drugs: is M1 agonism a pre-requisite for mimicking clozapine?s actions?
Psychopharmacology (2005)
-
Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia
Nature Reviews Drug Discovery (2004)